Blog

NEW YORK CITY, NY / ACCESS Newswire / August 21, 2025 / As the White House releases its America’s Talent Strategy: Building the Workforce for the Golden Age, state agencies are facing an urgent question: how to prepare workers for a job market being reshaped at unprecedented speed by AI and automation.

The challenge is clear. By 2030, 14% of workers will need to change jobs due to AI and automation, and 80% of the workforce will see disruption to their daily tasks from large language models like ChatGPT (McKinsey). Reemployment programs, built for a pre-AI economy, are struggling to keep pace.

The paradox is that the same technologies fueling disruption may also be the key to recovery.

Across the country, workforce agencies are piloting AI-powered assessments, virtual reality training, and AI-driven interview coaching to move people back into work faster and with better job matches.

“Over the last decade, I’ve watched hiring trends shift-but nothing compares to the pace of change we’re seeing now,” said Pamela Skillings, co-founder and chief coach at Big Interview. “AI isn’t just changing what jobs exist, it’s changing how quickly people need to adapt. Agencies that integrate these tools now will be the ones that keep their workers competitive.”

AI-enabled resume and interview tools-like those built into Big Interview-are helping states like Idaho provide personalized interview feedback to thousands of unemployed residents annually, without increasing staff workload.

These same approaches are in line with the White House’s America’s Talent Strategy Pillar IV and V priorities:

• Accountability: Linking investments to clear employment outcomes, shortening unemployment, and redirecting resources to programs that prove results.

• Flexibility & Innovation: Using AI-era tools to pilot new models, adapt training to labor market needs, and scale access to rural and underserved communities.

For state agencies, the impact is measurable. Big Interview’s AI-driven mock interview simulations and resume optimization tools have already supported over two million job seekers worldwide, helping them land jobs up to 5x faster than the national average.

“When you can serve thousands of people with personalized interview feedback-without adding staff-you’re not just innovating, you’re solving real problems,” said Steve Ruder, Vice President at Big Interview. “We’ve seen measurable results in multiple states, and the technology is proven to scale.”

As agencies evaluate their next steps under the America’s Talent Strategy report, one priority stands out: evaluate and pilot AI-driven tools that can scale impact, measure results, and adapt quickly to changing labor market needs.

Contact Information

Steve Ruder
Vice President
steve@biginterview.com

SOURCE: Big Interview

View the original press release on ACCESS Newswire

Canalevia^® (crofelemer delayed-release tablets), under the name Canalevia^®-CA1, is conditionally approved by the FDA for treatment of CID in dogs

Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally

Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

Enrollment has reached approximately 25% in Jaguar’s ongoing field study of Canalevia-CA1 in dogs

SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) (“Jaguar”), under its Jaguar Animal Health tradename for the veterinary market, today announced it is participating in the 2025 Animal Health Summit in support of the company’s goal of securing a collaboration to expand the indication of Canalevia (crofelemer delayed-release tablets) from treatment of chemotherapy-induced diarrhea (CID) in dogs to treatment of general diarrhea in dogs. Canalevia, under the name Canalevia-CA1, is conditionally approved by the U.S. Food and Drug Administration (FDA) for treatment of CID in dogs. The Animal Health Summit, hosted by KC Animal Health Corridor, takes place August 25-26, 2025 in Kansas City, Missouri.

“I’m pleased to report that Jaguar is currently in discussions with multiple potential animal health company partners regarding collaborating on the development, approval, and commercialization of Canalevia for treatment of general diarrhea in dogs,” said Lisa Conte, Jaguar’s Founder and CEO. “Specifically, our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in dogs; obtain approval in the European Union for Canalevia for treatment of general diarrhea in dogs based on existing Jaguar study data; maintain continuity of availability in the U.S. of Canalevia for treatment of CID in dogs. Forging a partnership to support these goals is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for Jaguar this year.”

“Our goal is to be as comprehensive as possible in the search for the best partner for Canalevia – and with this goal in mind we look forward to participating in the 2025 Animal Health Summit. Our team is available for partnership discussions at the event,” said David Sesin, PhD, Jaguar’s Chief Manufacturing Officer.

A report by the American Veterinary Medical Foundation concluded that there were approximately 90 million dogs in the U.S. in 2024, of which Jaguar estimates more than 11 million suffer from general diarrhea each year. Data from the European Pet Food Industry Federation concluded that there were approximately 104 million dogs in Europe in 2022. “We’ve been pleased with the marketplace reception of crofelemer for treatment of CID in dogs in the U.S. and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general diarrhea in dogs – both in the U.S. and the EU,” said Conte. “We estimate that U.S. veterinarians see approximately four million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general diarrhea in the U.S. and/or globally.”

As announced, enrollment has begun in Jaguar’s ongoing full effectiveness study of Canalevia-CA1 for the treatment of CID in dogs. With multiple veterinary oncology clinics signed on to take part in this study, enrollment has reached 25%, and Jaguar is in discussions with other veterinary oncology clinics regarding possible participation. The objective of this ongoing, prospective, randomized, open-label field study in dogs undergoing chemotherapy treatment across the U.S. is to collect real-world data to demonstrate real-world evidence of the clinical effectiveness for Canalevia-CA1 for the treatment of CID in dogs – the fourth and final technical section required to support potential full FDA approval of the drug for dogs with CID. Dogs enrolled in this study will be randomly assigned to receive a prescription of Canalevia-CA1 as a treatment for CID or be randomly selected for the control group.

Canalevia contains crofelemer, a plant-based botanical prescription drug that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics.

“In the EU, as we announced, it may be possible to obtain approval of Canalevia for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in 200 dogs with general diarrhea,” Conte said. “While this completed trial did not meet its stated primary endpoint, the study results are clinically significant when analyzed using an alternate endpoint, defining treatment success as any dog that had no episodes of diarrhea following the first treatment with either Canalevia or placebo. Using this revised endpoint, the study data shows that dogs treated with Canalevia resolved their diarrhea within 24 hours of the first administration of the drug, with the data demonstrating statistical and clinical relevance compared to placebo-treated dogs.”

Jaguar plans to submit a dossier to the European Medicines Agency (EMA) to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea. If acceptable to the EMA, the company will then submit a Marketing Authorization Application (MAA) for Canalevia for general diarrhea in dogs. If the application is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries.

Diarrhea is one of the most common reasons dogs are seen by general practice veterinarians and is the second most common reason for visits to veterinary emergency hospitals, yet there is currently no FDA-approved drug to treat general, non-infectious diarrhea in dogs. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of easy access to outdoor facilities is a significant problem for families living in urban settings with dogs.

Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar’s novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy.

About Conditional Approval and Full Approval

Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

About Chemotherapy-induced Diarrhea (CID) in Dogs

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer.¹ According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S.

Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,² and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs.

About Canalevia^®-CA1

Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a “small number” threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.

About Crofelemer

Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.

Important Safety Information About Canalevia^®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that company personnel will attend the 2025 Animal Health Summit, Jaguar’s expectation that it may be possible to obtain approval of Canalevia in the EU for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in dogs with general diarrhea, Jaguar’s expectation that it will submit a dossier to the EMA to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea, Jaguar’s expectation that, if the dossier is acceptable to the EMA, the company will then submit a MAA for Canalevia for general diarrhea in dogs to the EMA, and Jaguar’s expectation that, if the application is approved by the EMA, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹ “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

² Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

Source: Jaguar Health, Inc.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

BOCA RATON, FL / ACCESS Newswire / August 21, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced the appointment of David Gandler, Co-Founder and Chief Executive Officer of FuboTV Inc. (FUBO) (“Fubo”), as a Director to the Company’s Board of Directors, effective immediately.

“We are excited to add David Gandler to the Newsmax Board of Directors,” commented Christopher Ruddy, CEO of Newsmax. ” David’s achievements as an entrepreneur in the streaming and media industries will bring fresh perspective as we continue to expand our global reach, including through our streaming service Newsmax+. His success in building Fubo from startup to a leading operator in the space demonstrates the visionary leadership that will help Newsmax reach new audiences in today’s rapidly evolving media landscape.”

Mr. Gandler joins the five existing members of the Newsmax Board of Directors including Chief Executive Officer Christopher Ruddy, U.S. Secretary of Labor Alex Acosta, Ambassador Nancy Brinker, Christopher Nixon Cox and Ambassador Paula J. Dobriansky.

“I have long admired and respected Christopher Ruddy and his principled approach to journalism,” said Mr. Gandler. “Today’s 24/7 news cycle demands media companies deliver trusted information rapidly and through multiple distribution channels. I look forward to working with Chris and his Board of Directors to unlock new opportunities for Newsmax that will deepen audience engagement and accelerate growth.”

David Gandler

David Gandler is Co-Founder and CEO of Fubo, whose global mission is to aggregate the best in TV, including premium sports, news and entertainment content, through a single app.

Fubo listed on the New York Stock Exchange in October 2020, just five years after its founding. Fubo has ranked among The Americas’ Fastest-Growing Companies by the Financial Times (2025) and Forbes’ Next Billion Dollar Startups (2019).

Prior to founding Fubo in 2015, David had a prolific advertising career with more than 15 years of video sales in local broadcast and cable TV within both the general and Hispanic market, including at Scripps Networks Interactive, Time Warner Cable Media Sales and NBCUniversal’s Telemundo Media.

Beyond Fubo, David is a prominent figure in global sports and media. Through Gandler Sports Group (GSG), David is the majority owner and board member of soccer team Leyton Orient F.C. (EFL League One) and is a former co-owner of Paris FC. He also serves on the board of directors of Bare-Knuckle Fighting Championship (BKFC) and is a member of the esteemed Paley Media Council.

David has been named among Sports Business Journal’s Power Players: Sports Streaming (2025), Goldman Sachs’ 100 Most Intriguing Entrepreneurs (2019) and Variety’s Dealmakers (2020, 2019).

About Newsmax

Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major pay TV providers. Newsmax’s media properties reach more than 40 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches 20 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

For more information, please visit Investor Relations | Newsmax Inc.

Forward-Looking Statements

This communication contains forward-looking statements. From time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Forward-looking statements can be identified by those that are not historical in nature. The forward-looking statements discussed in this communication and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. Newsmax does not guarantee future results, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this communication to conform our prior statements to actual results or revised expectations, and we do not intend to do so. Factors that may cause actual results to differ materially from current expectations include various factors, including but not limited to our ability to change the direction of Newsmax, our ability to keep pace with new technology and changing market needs, the competitive environment of our business changes in domestic and global general economic and macro-economic conditions and/or uncertainties and factors set forth in the sections entitled “Risk Factors” in Newsmax’s Annual Report on Form 10-K for the twelve months ended December 31, 2024, Newsmax’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025, and other filings Newsmax makes with the Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Undue reliance should not be placed on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.

Investor Contacts

Newsmax Investor Relations
ir@newsmax.com

SOURCE: Newsmax Inc.

View the original press release on ACCESS Newswire

NEW YORK CITY, NEW YORK / ACCESS Newswire / August 21, 2025 / New to The Street today announced the launch of its newest segment, Unstoppable Entrepreneurs, co-produced and hosted by acclaimed entrepreneur and journalist Dr. Dustin Plantholt (Hon). The series will spotlight trailblazing leaders who are driving innovation, building resilient businesses, and shaping the future of their industries.

Filming for the inaugural episode begins next week and will feature an exclusive lineup of entrepreneurs and executives, including:

• Riadh Bouaziz, Chairman & CEO, RKF Group

• Paul Ziv, VP, Technology & Operations, TruAge Solutions LLC

• Dr. Mart McClellan, President, Macro Wealth Management

• Tim Hafner, CEO & Founder, OpenServ

The Unstoppable Entrepreneurs series will broadcast nationwide across New to The Street’s expansive media platform – including as sponsored programming on Bloomberg, as well as across FOX Business, YouTube, and the company’s extensive digital and social channels.

Vince Caruso, Co Founder & CEO of New to The Street, commented:

“At New to The Street, our mission has always been to spotlight companies and leaders that move industries forward. With Unstoppable Entrepreneurs, we’re doubling down on that promise. Dustin brings a unique storytelling ability that connects with entrepreneurs on a deeper level, creating content that not only inspires but also informs. This series will be a must-watch for anyone who wants to understand the mindset of those building tomorrow’s businesses.”

Dustin Plantholt, Co-Producer and Host, added:

“Entrepreneurs are the lifeblood of innovation and progress. Each one has a story of perseverance, vision, and determination that deserves to be told. I’m honored to partner with New to The Street to bring these stories to life and share the lessons of truly unstoppable individuals with a global audience.”

With the launch of Unstoppable Entrepreneurs, New to The Street continues to expand its reputation as a leading financial and business media platform, delivering unique, TV-ready earned media content with unmatched reach across broadcast, digital, and outdoor.

About Dustin Plantholt

Dr. Dustin Edward Plantholt (Hon) is an acclaimed journalist, entrepreneur, and AI architect. A former Senior Editor at Forbes Monaco and known globally as “The Count of Monte Crypto,” he has interviewed more than 500 changemakers – from heads of state to innovators, athletes, and artists. Named to the Forbes 40 Under 40 list and knighted by multiple royal houses, he has also received international humanitarian awards for his service and storytelling. His new Bloomberg program, Unstoppable Entrepreneurs, continues his mission to spotlight the people and ideas shaping the future.

About New to The Street

Since 2009, New to The Street has been one of the longest-running U.S. and international sponsored and syndicated television brands. The platform has produced and broadcast more than 3,000 interviews, reaching millions of homes across FOX Business, Bloomberg, and other networks, while also distributing content to over 3.2M YouTube subscribers and a robust global social media audience.

Media Contact:
Monica Brennan
Monica@NewtoTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

JERUSALEM, IL / ACCESS Newswire / August 21, 2025 / AppYea Inc. (OTCQB:APYP) today announced a strategic business pivot with the acquisition of Techlott Ltd.’s proprietary blockchain-based lottery and gaming platform. The transaction refocuses AppYea on the rapidly growing institutional lottery market, providing a complete, production-ready technology package engineered for enterprise deployments.

Why Techlott is a Game-Changer?

Techlott’s platform addresses the core weaknesses of legacy lottery systems-high costs, opacity, and slow scaling. Its Web3 architecture is built for today’s market:

• Engineered for Public Trust: The system puts governance and compliance at its core. It features on-chain draw logic, verifiable randomness, and an immutable audit trail-all essential for regulators and government ministries. This design helps build public trust by providing full transparency.

• Significantly Lower Operating Costs: Unlike legacy systems that rely on complex infrastructure and large back-office teams, Techlott’s design automates core workflows and reduces operational overhead. We project this can lead to up to significant lower operating costs for our partners.

• Security and Readiness: The platform’s smart contracts have passed an independent QuillAudits review with no high or medium-severity issues. The system has successfully processed over 212,000 test transactions under transparency review, validating its readiness for national-scale use.

• Built for Flexibility: The stack supports B2G, B2B, and B2C models, allowing for broad commercial deployment. It integrates with multiple blockchain networks and supports hybrid fiat-crypto payments.

Global Lottery Market: A Massive, Under-Digitized Opportunity

Independent market data consistently shows a very large and expanding market:

• Grand View Research: $353.29B (2024), forecast to reach $483.93B by 2030.

• Verified Market Research: $327.44B (2024), forecast to reach $402.42B by 2032.

With only ~16% of global lottery activity currently online, the market is poised for digital migration. Techlott’s platform is uniquely positioned to capture this significant opportunity.

Next Steps & Capital Markets

As part of the transaction, AppYea is aligning with Techlott’s team, with Techlott becoming a significant shareholder and gaining board representation. We will focus on:

1. Technology Integration & Commercialization: Rapidly integrating the platform and initiating go-to-market efforts focused on government and enterprise deployments.

2. Applying to uplist to a US Exchange: Advancing preparations for a potential uplisting application and related financing activities to support scaled operations.

Executive Commentary

Yakir Abadi, Chief Executive Officer, AppYea:

“This acquisition is the culmination of a clear strategy. We identified a gap in a multi-billion dollar market and acquired the technology to fill it. Regulators and ministries worldwide are seeking transparency and efficiency, and Techlott delivers exactly that. Our plan is simple and focused: integrate, sign anchor partners, and prepare for our next chapter on a major exchange.”

Mark Katzenelson, Founder, Techlott:

“After years of development and millions of dollars invested, our platform is ready for prime time. Teaming with AppYea gives us the public-market presence and governance needed to deploy our technology at institutional and national scale. This partnership is a catalyst for our growth.”

Eldar Edmond Grady, Chairman, AppYea:

“We are now a technology-driven company with a clear product, a solid execution plan, and a path to growth. Our focus is on disciplined delivery: bringing the technology to market, securing key contracts, and strengthening our capital structure to drive long-term value for our shareholders.”

Additional information on the transactions are provided in AppYea’s current report on Form 8-K filed with the Securities and Exchange Commission.

About Techlott Ltd.

Techlott Ltd. is a Cyprus‑incorporated technology company specializing in lottery and gaming platforms for regulated environments. Under the parties’ definitive agreements, AppYea is acquiring Techlott’s software (including source code), documentation, and related IP, positioned for institutional‑grade commercialization.

Safe Harbor Statement:

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of AppYea are subject to many factors including, but not limited to, the sufficiency or working capital to realize our business plans and new strategic direction, the going concern qualification in our financial statements, our ability to penetrate the new intended markets, our success in integrating the platform and initiating go-to-market efforts, our success in uplisting to a US exchange, the introduction of competitive products, the impact of any adverse litigation, commercialization and technological difficulties, and the other risks identified in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on April 15, 2025. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.

Investor Relations Contact:
Golmidas Communications
Email: info@golmidas.com

SOURCE: APPYEA, Inc.

View the original press release on ACCESS Newswire

CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences:

Morgan Stanley’s 23^rd Annual Global Healthcare Conference, on Monday, September 8^th at 10:00am ET

Bernstein Insights: Healthcare Leaders and Disruptors, on Thursday, September 25^th at 10:30am ET

A live webcast of each of these presentations will be available under “Events and Presentations” in the Investors section of the Moderna website.

investors.modernatx.com.

A replay of each webcast will be archived on Moderna’s website for at least 30 days following the presentation.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Media Contacts

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

Advanced Care Specialists is Bringing Not Just Medical Care, but True Advocacy

RACINE, WISCONSIN / ACCESS Newswire / August 21, 2025 / Advanced Care Specialists (ACS), Racine’s premier provider of multidisciplinary medical care, is proud to announce a renewed focus on helping injured workers with a streamlined, patient-first approach that’s changing the face of occupational injury treatment in Wisconsin.

The Problem: Delays, Denials, and Disjointed Care

Every year, countless Wisconsin workers suffer injuries on the job, ranging from repetitive strain and back pain to traumatic incidents and long-term occupational illnesses. Unfortunately, many face a frustrating road to recovery, especially federal workers trying to navigate the complex Department of Labor (DOL-OWCP) claims process. Between confusing paperwork, denied claims, and a lack of specialized medical support, injured workers are often left feeling overwhelmed and under-cared for.

That’s where Advanced Care Specialists steps in.

The Solution: Comprehensive, Coordinated Care Under One Roof

ACS provides a one-stop solution for injured workers, offering medical care, physical therapy, chiropractic services, joint injections, and advanced Class IV infrared laser therapy-all in one location. What truly sets them apart is their expertise in managing federal injury cases, guiding patients through CA-1 and CA-2 forms, coordinating with case managers, and even helping appeal denied claims. Their work conditioning programs are uniquely designed to get patients back to work stronger, safer, and fully prepared for the demands of their job.

As the only clinic in the state specializing in DOL-OWCP federal work injury claims, ACS offers a full-service solution for workers navigating the complex world of federal workers’ compensation. From initial injury reports (CA-1 and CA-2) to case management, appeals, and long-term treatment, ACS guides patients every step of the way. Helping patients recover faster, return to work safely, and regain quality of life.

“We believe injured workers deserve more than a Band-Aid fix. Our mission is to get them back to full strength, back to their lives, and back to work-safely and confidently,” said Dr. Nic Kampfer, Work Injury Specialist at ACS. “We’re not just treating injuries; we’re restoring function, dignity, and hope.”

Why ACS is Making Headlines:

• Unmatched Expertise: ACS is the only clinic in Wisconsin fully equipped to handle federal work injury cases through the Department of Labor’s Office of Workers’ Compensation Programs (OWCP).

• Comprehensive Care: Services include physical therapy, chiropractic care, massage therapy, joint injections, and Class IV infrared laser therapy, and more -all under one roof.

• Work Conditioning Programs: Tailored to each patient’s job and goals, ensuring a safe and sustainable return to work.

• Patient Advocacy: ACS empowers workers to know their rights-including the right to choose their doctor-and helps them cut through the red tape of injury claims.

Whether you’re a federal employee, postal worker, or anyone hurt on the job, ACS is your partner in recovery.

For more information, visit advancedcarespecialists.com/services/work-injury or call (262) 898-9000.

About Advanced Care Specialists
Advanced Care Specialists (ACS) is a multidisciplinary medical clinic proudly serving the Racine, Wisconsin community with a commitment to delivering high-quality, patient-centered care. ACS offers a wide range of services including primary care, physical therapy, chiropractic care, interventional pain management, advanced wound care, hyperbaric oxygen therapy, regenerative medicine, massage therapy, and specialized programs for work injuries and federal workers’ compensation (DOL-OWCP). With an integrated team of healthcare professionals and a focus on collaborative treatment, ACS is dedicated to helping patients achieve lasting relief, improved mobility, and better overall health. Whether recovering from injury, managing chronic conditions, or striving for wellness, ACS is a trusted partner in long-term care and healing. For more information, visit www.advancedcarespecialists.com or call (262) 898-9000.

Media Contact:
Hannah Kearney
Marketing & Communications
Advanced Care Specialists
Email: info@advancedcarespecialists.com
Phone: (262) 898-9000

SOURCE: Advanced Care Specialists

View the original press release on ACCESS Newswire